Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain

Nina Reiners 1 · Carolin Schnurra 1 · Henning Trawinski 2 · Judith Kannenberg 1 · Thomas Hermsdorf 3 · Andrea Aebischer 4 · Torsten Schöneberg 3 · Sven Reiche 4 · Christian Jassoy 1

Received: 1 April 2021 / Accepted: 27 May 2021 / Published online: 4 June 2021
© The Author(s) 2021

Abstract

SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient.

Keywords SARS CoV-2 · Nucleoprotein · Receptor-binding domain · COVID-19 · Antibodies · ELISA

Introduction

Infection with the SARS CoV-2 induces a virus-specific immune response [1–4]. IgG antibodies against the virus indicate previous infection and examination of the antibody response in a population provides information about the level of exposure to the virus [5–8].

Commercial SARS CoV-2 antibody tests are based on measuring antibodies against the viral nucleoprotein (NP); the spike glycoprotein regions S1, S2, or the receptor-binding domain (RBD); or, more rarely, a combination of two viral proteins [9–15]. Antibody tests based on either the NP or the spike protein have similar sensitivity but react with slightly different sets of sera [16–19]. This suggests that tests that concurrently measure antibodies against the two proteins are more sensitive than tests for antibodies against only NP or the spike glycoprotein. Based on this assumption, the aim of the study was to examine if simultaneous testing for IgG against the NP and RBD recognizes more sera than testing for antibodies against NP or RBD alone.

Study design

We performed a diagnostic study to compare the diagnostic sensitivity and specificity of IgG antibody ELISAs based on SARS CoV-2 NP, RBD, or the two proteins simultaneously.

Serum samples

Serum (N=91) and plasma (N=89) collected before 2019 were tested as putative negative specimens. Plasma and 80 sera were from blood donors (Institute for Transfusion Medicine, University Clinics, University of Leipzig). Eleven sera were from laboratory personnel. Ninety-eight sera were from adults with a positive SARS CoV-2 RT-PCR and mild to moderate
or no symptoms. Forty-eight of the sera were obtained 4–10 weeks after infection; 50 blood specimens were drawn 6 months after infection. Participants were infected in March or April 2020. The sera from 4–10 weeks have previously been used to compare the sensitivity of commercial antibody tests [18]. Most (46 of 50) of the sera were from the same individuals.

### Viral antigens

The SARS CoV-2 nucleoprotein was produced in *Escherichia coli* as a maltose-binding domain fusion protein. The receptor-binding domain (RBD) was generated as a strep-tag fusion protein in Expi293 cells (see Suppl. Material S1).

### Antibody ELISA

Antibody ELISAs were performed with antigen-coated microtiter plates according to a modified standard protocol (see Suppl. Material S2).

### Calibrator and cut-off value

A SARS CoV-2 antibody–positive serum prediluted in a protein stabilizer (Antibody Stabilizer PBS, Candor Bioscience GmbH) was used as the calibrator sample. To establish the calibration factor, the calibrator and 91 control sera from before 2019 were tested in parallel on the same plate. The calibration factor was calculated as the ratio of the OD of the calibrator serum and the mean plus two standard deviations of the OD of the control sera. In subsequent assays with plasma and sera, the cut-off was calculated by dividing the OD of the calibrator sample by the calibration factor.

### Data analysis

Measurement units (U) were calculated by dividing the OD of the serum sample by the cut-off OD. As a start, sera with less than 1.0 U were negative and sera higher than 1.0 were positive. Receiver operating characteristic (ROC) analysis was performed and the cut-off values of the tests were adjusted such that the ELISAs had similar specificity. Sensitivity and specificity of the ELISAs were calculated with a contingency table and ROCs were calculated with a spreadsheet program. The area under the receiver operating characteristic curve (AUROC) was calculated with the MedCalc statistical software and the AUROCs were compared with VassarStats (http://vassarstats.net/index.html). The 95% confidence intervals were calculated using the MedCalc “Test for one proportion” and the Clopper-Pearson confidence interval. Proportions of unpaired serum samples were compared with the MedCalc “Comparison of proportions calculator” that uses the chi-squared test.

### Results

#### Area under the receiver operating characteristic curve (AUROC)

Receiver operating characteristic analysis was performed to determine the AUROC as a measure for the discrimination level of the tests. The AUROCs of the NP-, RBD-, and NP/RBD-based test were 0.958 (95% confidence interval (CI): 0.927–0.978), 0.991 (95% CI: 0.971–0.998), and 0.992 (95% CI: 0.974–0.999), respectively. The AUROC of the RBD- and NP/RBD-based assays was significantly larger than the AUROC of the NP-based ELISA (p-values 0.039 and 0.032, Table 1).

#### Comparison of the sensitivity of the assays

To compare the diagnostic sensitivity of the tests, the cut-offs of the ELISAs were adjusted to a specificity of 98.33% by ROC analysis. The cut-off values were taken to determine the sensitivity of the tests with sera from SARS CoV-2-infected individuals. The NP-based ELISA found antibodies in 81 of the sera (82.7%, 95% confidence interval (CI): 73.7–89.6%). The RBD-based test showed 91 positive results (92.9%, 95% CI: 85.9–97.1%) and the NP/RBD-based assay recognized 94 (95.9%, 95% CI: 89.9–97.9%) of the sera. Subgroup analysis with the 48 sera obtained 4–10 weeks after infection showed positivity rates of 95.8% (95% CI: 85.7–99.5%), 97.9% (95% CI: 88.9–99.5%), and 100% (95% CI: 92.6–100%). The 50 sera from 6 months after infection gave 70.0% (95% CI: 55.4–82.1%), 88.0% (95% CI: 75.7–95.5%), and 92.0% (95% CI: 80.8–97.8%) positive results. The diagnostic sensitivity of the NP-based and NP/RBD-based tests was lower with sera from 6 months than from early after infection (Table 2).

The difference in sensitivity of the tests at 4-10 weeks after infection was statistically insignificant, but the RBD- and NP/RBD-based tests were more sensitive than the NP-based ELISA.

### Table 1

|         | NP          | RBD         | NP/RBD      |
|---------|-------------|-------------|-------------|
| AUROC   | 0.958       | 0.991*      | 0.992*      |
| CI      | [0.927; 0.978] | [0.971; 0.998] | [0.974; 0.999] |

*p-values of two-tailed comparisons of the AUROC of the antibody assays. NP- and RBD-based ELISA: 0.039, NP- versus NP/RBD-based ELISA: 0.032
ELISA with the sera from 6 months after infection ($p = 0.0413$ and $0.0002$). The NP/RBD-based ELISA showed a higher percentage of positive results compared with the RBD-based antibody assay, but this was not statistically different (Table 3). Five sera that were positive in the NP ELISA and negative in the RBD test were positive in the NP/RBD-based ELISA (Supplementary Table 1).

### Discussion

Most commercial SARS CoV-2 antibody tests measure the antibody response against either the viral NP or portions of the spike glycoprotein. Some tests measure antibodies against both NP and the spike protein [9, 13, 15, 20–22]. We investigated if simultaneous testing with the NP and RBD improves the diagnostic sensitivity of SARS CoV-2 antibody testing compared with testing for antibodies against the NP and RBD alone.

The diagnostic sensitivity and specificity of the ELISAs were in the same range as commercial NP- and spike glycoprotein–based SARS CoV-2 ELISA tests [18, 23–27].

### Table 2

| Time post infection | No. of sera | Positive sera (%) | CI [95% confidence interval] | CI [95% confidence interval] | CI [95% confidence interval] |
|---------------------|-------------|-------------------|-----------------------------|-----------------------------|-----------------------------|
| > 4 weeks           | 98          | 82.7              | CI [73.74; 89.60]           | CI [89.85; 98.87]           |
| 4–10 weeks          | 48          | 95.8              | CI [92.60; 100.0]           | CI [85.70; 99.48]           |
| 6 months            | 50          | 92.0              | CI [80.77; 97.78]           | CI [85.89; 97.11]           |
| p-levelb            |             | 0.0008*           | 0.0585                      | 0.0465*                     |

*a* CI: 95% confidence interval

*b* Comparison of the sensitivity 4–10 weeks versus 6 months post infection by the chi-squared test. Significant p-values are labeled with an asterisk

### Table 3

| Time post infection | ELISA | RBD | NP/RBD | RBD | NP/RBD | RBD | NP/RBD |
|---------------------|-------|-----|--------|-----|--------|-----|--------|
| > 4 weeks           | NP    | 0.049b* | 0.0009* | 1   | 0.5    | 0.0413* | 0.0002* |
| 4–10 weeks          | RBD   | x    | 0.687  | x   | 1      | x    | 0.453  |
| 6 months            | NP/RBD|      |        |     |        |      |        |

*a* RBD, receptor-binding domain; NP, nucleoprotein

*b* p-values. Sensitivity values from Table 1 were compared with the exact binomial test. An asterisk indicates statistical significance at a significance level of 0.05

The AUROC of the NP-based test was significantly smaller than those of the RBD- and NP/RBD-based ELISAs indicating that the NP-based ELISA has lower discriminatory potency. Among the other two assays, the NP/RBD-based test recognized more sera than the RBD-based ELISA. Several sera that were negative in the RBD-based ELISA were positive in both the NP-based and the NP/RBD-based ELISAs. However, the risk of false positive results also increased. With the samples examined, the AUROC and the diagnostic sensitivity of the combined antibody test were slightly higher than those of the RBD-based assay, but this was not statistically significant.

The results are similar to those recently obtained with a Luminex-based SARS CoV-2 antibody test that simultaneously measured antibodies against NP, RBD, and other spike protein fractions [22].

We also evaluated the percentage of positive results with sera from different time points. The three ELISAs showed more positive results with sera obtained at 4–10 weeks after infection. In that time period, the NP-, RBD- and NP/RBD-based IgG ELISAs showed comparable proportions of positive sera. When tested with sera obtained 6 months after infection, the RBD- and NP/RBD-based tests detected more sera than the NP-based ELISA. The lower rate of positive results is most likely due to the slightly shorter half-life of NP-specific antibodies in the serum compared to spike glycoprotein–specific antibodies [28–30].

The lower limits of detection of the NP- and RBD-based ELISAs were approximately 30 and 10 IU/ml (First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, NIBSC code 20/136, data not shown). The analytical sensitivity remains unaffected by the antibody concentration in the sera. The loss of diagnostic sensitivity shown here is due to the decline of SARS CoV-2 antibodies after infection [28–30].

The main technical limitation of the ELISAs is the occurrence of false positive sera and plasma. Sera that were false positive in the NP- or the RBD-based ELISA reacted with the NP/RBD-based ELISA. A similar observation was previously
made with a Luminex-based antibody test [22]. Thus, although the sensitivity of the ELISA with the two proteins increased, the specificity declined concomitantly. Interestingly, the false positive sera were negative when tested in the nucleoprotein-based Roche Elecsys and the RBD-based Siemens Atellica IM COV2T antibody bridging assays (data not shown). This suggests that further improvement of the ELISA technique may reduce the frequency of false positive reactions.

Most vaccines against SARS CoV-2 induce immune responses against the spike glycoprotein but not the nucleoprotein. Therefore, tests that detect antibodies against the viral NP do not measure vaccine-induced antibodies. On the other hand, NP-specific antibodies are a sign of previous infection. Ideally, SARS CoV-2 antibody tests provide information to differentiate between previous infection and immunization.

In summary, the SARS CoV-2 RBD-specific antibody ELISA was diagnostically more sensitive than the NP-specific ELISA. Simultaneous measurement of NP- and RBD-specific antibodies further increased the percentage of positive sera, but this was not statistically significant due to small sample size. The ELISAs showed fewer positive results with sera from 6 months after infection compared with sera from early time points. The loss of diagnostic sensitivity was most pronounced with the nucleoprotein-specific assay. This suggests that assays using the RBD or NP/RBD are better for serosurveillance beyond 6 months after infection.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s10096-021-04284-5](https://doi.org/10.1007/s10096-021-04284-5).

**Acknowledgements** The study was approved by the Ethics Committee of the Medical Faculty of the University of Leipzig. The authors thank T. Kaiser, R. Biemann (Institute for Laboratory Medicine, University Hospitals, University of Leipzig), and H. Zaiß (Labor alphaomega, Kaiser, R. Biemann (Institute for Laboratory Medicine, University Hospitals, University of Leipzig)) for re-testing of several sera with the Roche Elecsys anti-SARS-CoV-2 and Siemens Atellica IM COV2T tests.

**Code availability** Not applicable.

**Author contribution** Nina Reiners: methodology, formal analysis, investigation, writing—review and editing. Carolin Schnurr: methodology, investigation, formal analysis, writing—review and editing. Henning Trawinski: methodology, resources, writing—review and editing. Andrea Aeberscher: methodology. Sven Reiche: methodology. Torsten Schöneberg: methodology. Christian Jassoy: conceptualization, methodology, formal analysis, writing—review and editing.

**Funding** Open Access funding enabled and organized by Projekt DEAL. The research was made possible through institutional funds.

**Data availability** Original data will be made available upon request.

**Declarations**

**Ethics approval** The study was performed in line with the principles of the Declaration of Helsinki. It was approved by the Ethics Committee of the Medical Faculty of the University of Leipzig.

**Consent to participate** Oral and written informed consent was obtained from the participants.

**Consent for publication** The authors have seen the final version of the manuscript and approved submission for publication.

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

1. Poland GA, Ovsyannikova IG, Kennedy RB (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 396:1595–1606. [https://doi.org/10.1016/S0140-6736(20)32137-1](https://doi.org/10.1016/S0140-6736(20)32137-1)

2. Sun B, Feng Y, Mo X et al (2020) Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 9:940–948. [https://doi.org/10.1080/22221751.2020.1762515](https://doi.org/10.1080/22221751.2020.1762515)

3. Wölfel R, Corman VM, Guggemos W et al (2020) Virological assessment of hospitalized patients with COVID-19. Nature 581:465–469. [https://doi.org/10.1038/s41586-020-2196-x](https://doi.org/10.1038/s41586-020-2196-x)

4. Zhao J, Yuan Q, Wang H et al (2020) Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 71:2027–2034. [https://doi.org/10.1093/cid/ciaa344](https://doi.org/10.1093/cid/ciaa344)

5. Anand S, Montez-Rath M, Han J et al (2020) Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis: the USA: a cross-sectional study. Lancet. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32009-2/fulltext)

6. Deeks J, Dinnes J, Takwoingi Y et al (2020) Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 6:CD013652. [https://doi.org/10.1002/14651858.CD013652](https://doi.org/10.1002/14651858.CD013652)

7. Lai C-C, Wang J-H, Hsueh P-R (2020) Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review. Int J Infect Dis 101:314–322. [https://doi.org/10.1016/j.ijid.2020.10.011](https://doi.org/10.1016/j.ijid.2020.10.011)

8. Pollán M, Pérez-Gómez B, Pastor-Barriuso R et al (2020) Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 396:535–544. [https://doi.org/10.1016/S0140-6736(20)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5)

9. Gillet C, Douxfils J, Cadrobbi J et al (2020) An original ELISA-based multiplex method for the simultaneous detection of 5 SARS-CoV-2 IgG antibodies directed against different antigens. J Clin Med 9. [https://doi.org/10.3390/jcm9113752](https://doi.org/10.3390/jcm9113752)

10. Long Q-X, Liu B-Z, Deng H-J et al (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845–848. [https://doi.org/10.1038/s41591-020-0897-1](https://doi.org/10.1038/s41591-020-0897-1)
11. Mairesse A, Favresse J, Eucher C et al (2020) High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clin Biochem 86:23–27. https://doi.org/10.1016/j.clinbiochem.2020.08.009

12. Pérez-García F, Pérez-Tanoira R, Iglesias ME et al (2021) Comparative evaluation of six immunoassays for the detection of antibodies against SARS-CoV-2. J Virol Methods 289:114047. https://doi.org/10.1016/j.jviromet.2020.114047

13. Shi J, Han D, Zhang R et al (2020) Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics. Clin Chem 66:1030–1046. https://doi.org/10.1093/clinchem/hvaa122

14. Strömer A, Rose R, Grobe O et al (2020) Kinetics of nucleo- and spike protein-specific immunoglobulin G and of virus-neutralizing antibodies after SARS-CoV-2 infection. Microorganisms 8. https://doi.org/10.3390/microorganisms8101572

15. Trabaud M-A, Icard V, Milon M-P et al (2020) Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol 132:104613. https://doi.org/10.1016/j.jcv.2020.104613

16. Brochot E, Demey B, Handala L et al (2020) Comparison of different serological assays for SARS-CoV-2 in real life. J Clin Virol 130:104569. https://doi.org/10.1016/j.jcv.2020.104569

17. Liu W, Liu L, Kou G et al (2020) Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol 58. https://doi.org/10.1128/JCM.00461-20

18. Schnurra C, Reiners N, Biemann R et al (2020) Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J Clin Virol 129:104544. https://doi.org/10.1016/j.jcv.2020.104544

19. Theel ES, Harring J, Hilgart H, Granger D (2020) Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 58. https://doi.org/10.1128/JCM.01243-20

20. Bray RA, Lee J-H, Brescia P et al (2021) Development and validation of a multiplex, bead-based assay to detect antibodies directed against SARS-CoV-2 proteins. Transplantation 105:79–89. https://doi.org/10.1097/TP.0000000000003524

21. Grossberg AN, Koza LA, Ledreux A et al (2021) A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nat Commun 12. https://doi.org/10.1038/s41467-021-21040-7

22. Marién J, Ceulemans A, Michiels J et al (2021) Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods 288:114025. https://doi.org/10.1016/j.jviromet.2020.114025

23. Hanssen DAT, Slaats M, Mulder M et al (2021) Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-021-04220-7

24. Kohner N, Westhaus S, Rühl C et al (2020) Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol 92:2243–2247. https://doi.org/10.1002/jmv.26145

25. Krüttgen A, Cornelissen CG, Dreher M et al (2020) Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. J Clin Virol 128:104394. https://doi.org/10.1016/j.jcv.2020.104394

26. Peterhoff D, Glück V, Vogel M et al (2021) A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection 49:75–82. https://doi.org/10.1007/s13010-020-01503-7

27. Roy V, Fischinger S, Attyoe C et al (2020) SARS-CoV-2-specific ELISA development. J Immunol Methods 484–485:112832. https://doi.org/10.1016/j.jim.2020.112832

28. Dan JM, Mateus J, Kato Y et al (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371. https://doi.org/10.1126/science.abf4063

29. Iyer AS, Jones FK, Nodoushani A et al (2020) Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 5. https://doi.org/10.1126/sciimmunol.abo0367

30. Rodda LB, Netland J, Shehata L et al (2021) Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184:169–183.e17. https://doi.org/10.1016/j.cell.2020.11.029

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.